When Will American Patients Start Benefitting From Biosimilars?

Mayo Clin Proc. 2022 Jun;97(6):1044-1047. doi: 10.1016/j.mayocp.2022.04.013.

Authors

Arnold G Vulto¹, Liese Barbier²

Affiliations

¹ ErasmusMC Hospital Pharmacy, Rotterdam, The Netherlands; KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, MABEL Research Fund, Leuven, Belgium. Electronic address: a.vulto@gmail.com.
² KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, MABEL Research Fund, Leuven, Belgium.

PMID: 35662421
DOI: 10.1016/j.mayocp.2022.04.013

No abstract available

Publication types

Editorial
Comment

MeSH terms

Biosimilar Pharmaceuticals* / therapeutic use
Humans
United States

Substances

Biosimilar Pharmaceuticals